Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains - Wikidata - wikimedia - TriplyDB

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

http://www.wikidata.org/entity/Q33613660

about

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections Targeting Antibiotic Resistance Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Strain-tailored double-disk synergy test detects extended-spectrum oxacillinases in Pseudomonas aeruginosa.In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.Crataeva nurvala nanoparticles inhibit virulence factors and biofilm formation in clinical isolates of Pseudomonas aeruginosa.β-Lactam Antibiotics Renaissance.In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.β-Lactam antimicrobials: what have you done for me lately?Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain.In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania.Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study.Antiquorum sensing activity of silver nanoparticles in P. aeruginosa: an in silico study.Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.Small-Molecule Inhibitors of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity

P2860

Q28069563-AAADB6E7-57DD-4078-9F23-25CC874B3BF7 Q28078130-8A1B8EB1-EE27-44CC-AE3C-96CF7DC64E13 Q34045418-236FC94D-FD0B-47FA-BEE4-A1EE592B233E Q34164594-5FE7502A-8C77-4BCF-9339-0B4986230FE4 Q34299064-EF3A8256-3641-4302-A811-9769278AB18B Q34320027-E4A7F0CC-8B21-4539-A617-A355CB195F47 Q34393008-13B56AD0-AB0F-42B6-9950-38703CB458DC Q35066737-EEF8E895-53C1-45E9-B186-B28E5E6FBF9E Q35666617-301F1E03-E023-470C-96A6-F856A465F46B Q36172484-82BE7094-1BBA-4591-B357-ED283CC3310F Q36200910-91957DBD-193A-46BC-9B16-CB274869F477 Q36683689-E9A65A5B-2714-4953-9B24-EA92E3955894 Q37263317-98FF9912-3867-4846-9B28-1096A4370CD7 Q37538614-0E2B5E92-9FEE-4C3C-86C3-E0271444B1A7 Q38076453-EEB3A20F-FF59-4CF7-843D-6AEBB7026314 Q38115356-5522D4DF-D72F-4FF9-8E13-F92DB8E7607B Q38241417-1CC94721-AED3-4219-93B8-737141BDA163 Q38262205-7A7BB5F3-446F-425D-BCD5-DC69BE5E04ED Q38267323-29C97187-7D76-4AC8-A28E-FBBA25AE1E3C Q38872130-12380B5E-9DED-4FF9-B430-0633F66AE7A5 Q39037981-06AEF7A9-840D-4274-A947-EF58D1F5DDC8 Q40056971-DA6D71C0-89CD-4158-BB81-7E18A9874CC1 Q40148490-FDE13C56-60CE-4854-85D2-00F0BDF5F5EA Q40755542-EB5BC6AC-4965-42BD-8081-7B32969C787F Q40882363-8743D8C4-D428-47C6-BC08-64D39C1F2348 Q41075944-6CFAFD9A-7AB8-4D14-AE60-267CD4306A87 Q41695599-3D2C374A-4F17-4277-99D4-0C07EC1CF9E7 Q41839265-F86DA69C-AC13-44FD-BB44-3E9910C361DB Q42245248-83B8711D-2A50-4C31-8E4C-082E05DBB729 Q42430254-70677B0F-444A-45C8-8E55-E223F27DE67F Q43126004-9021A465-66A2-4C2B-B813-B56A4E73EBF3 Q44053339-76CA51AD-4ABC-4CC8-97E2-124C85B2D28B Q46958203-D93B79B4-ACF2-4297-831D-132EDECA5FBD Q47446874-CEB9D96E-6B4D-44BD-82D5-6E278A18D166 Q47748447-F06FE354-76F4-4C6F-A192-F191E6C88C3E Q49921578-93ADB18C-59ED-4A87-9DA4-E79F2CA0B710 Q58200362-110BEAA9-5A32-463D-BE44-8DC3153F6128

P2860

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

http://www.wikidata.org/entity/Q33613660

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@ast

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@en

type

label

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@ast

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@en

prefLabel

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@ast

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@en

P1433

Q33613660-92E086A4-2022-4B58-871E-78AF18858D98

P1476

Q33613660-B4DF7CC4-C033-46B7-9D38-7B9B3B99650D

P2093

Q33613660-0560CB51-416C-41DD-9914-32A873236F9A

Q33613660-0F4F2877-D425-43BE-9FF2-551857D3C7D4

Q33613660-3DCF3BE4-2335-4DB7-A6D2-5FAC14710272

Q33613660-4AD942EB-D9B3-44FE-9F50-85E1A6390803

Q33613660-84374C2E-243C-4CA1-BD90-3E27D699EE76

Q33613660-96C9675C-ADE6-4FB2-B83A-E2521C1F6EA3

Q33613660-A56CC384-BEF3-4680-ADBF-5652E6EBA6A8

P2860

Q33613660-0E6B9C2A-7F43-4CE7-8774-6C06F7812A26

Q33613660-0FDD485C-E703-4F88-9147-B46137F75A20

Q33613660-2F5BFA35-8FBF-4C53-9724-549CCDE91045

Q33613660-44B1990A-210B-4F67-B009-5A326F98654A

Q33613660-4B726C02-AF3B-4F5E-BADF-5EDA4D7125D4

Q33613660-546160F2-750F-4B55-887E-F060D3858FE3

Q33613660-5634F922-6244-401A-BF45-917D7D161B3B

Q33613660-64206C64-8BE2-4AC2-AB74-1DBC538FAF5F

Q33613660-657C82B4-932F-48CF-9049-AEC53378C901

Q33613660-725119D7-8A85-4136-92B8-48B917BE44B9

P304

Q33613660-55D9A9C1-FB4B-493B-B60C-61056DB11EB6

P31

Q33613660-6125ABDA-9641-4642-9657-56C384DF3B7E

P356

Q33613660-9A519DE7-E4B5-4208-A0F4-507A0F1B12DA

P407

Q33613660-5DECEED4-1279-41C3-BF7A-04B0C7BE6E67

P433

Q33613660-F41C2F31-A69D-4C68-983C-216D9FBB957F

P478

Q33613660-9DC3A43F-5AF7-46C1-BEB0-E74AB766AFF6

P577

Q33613660-260FC7C8-20DE-48C0-9B2C-8F52B073FC7C

P5875

Q33613660-62B97EDD-CC4C-4D33-A71A-4F978889F914

P698

Q33613660-CE42089A-3392-4889-B967-A7B0181CDB81

P921

Q33613660-3C01145B-D7CF-4C0F-9E22-9E2AE271A1DB

Q33613660-9264D5AE-D8A7-42B5-BA3C-E920FB42BDDA

Q33613660-BC6471EF-A71E-4273-AE10-59E3050D45D1

P932

Q33613660-0CD11E32-0C09-44BD-8E27-65C3B80E7B13

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Activity of a new antipseudomo ...... as aeruginosa clinical strains

@en

P2093

Antonio Oliver

http://www.w3.org/2001/XMLSchema#string

Carlos Juan

http://www.w3.org/2001/XMLSchema#string

José L Pérez

http://www.w3.org/2001/XMLSchema#string

Laura Zamorano

http://www.w3.org/2001/XMLSchema#string

Spanish Group for the Study of Pseudomonas

http://www.w3.org/2001/XMLSchema#string

Spanish Network for Research in Infectious Diseases

http://www.w3.org/2001/XMLSchema#string

Yigong Ge

http://www.w3.org/2001/XMLSchema#string

P2860

Efflux-mediated multiresistance in Gram-negative bacteria

Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa

Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate.

Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein.

Metallo-beta-lactamases: the quiet before the storm?

Genetic environment and expression of the extended-spectrum beta-lactamase blaPER-1 gene in gram-negative bacteria.

BEL-1, a novel clavulanic acid-inhibited extended-spectrum beta-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa

Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene.

In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette.

P304

846-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00834-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40027143

http://www.w3.org/2001/XMLSchema#string

P698

19933793

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

carbapenem antibiotic

multiple drug resistance

P932

2812131

http://www.w3.org/2001/XMLSchema#string